CLAIMS

1. Use of an Eribulin mesylate liposomal formulation in the manufacture of a pharmaceutical composition for treating tumor, wherein the pharmaceutical composition is to be administered in combination with a programmed cell death 1 protein (PD-1) antibody, and wherein the tumor is breast cancer, gastric cancer, esophageal cancer, small cell lung cancer, colorectal cancer, renal cancer, thymic carcinoma or intrahepatic cholangiocarcinoma.

2. Use of a PD-1 antibody in the manufacture of a pharmaceutical composition for treating tumor, wherein the pharmaceutical composition is to be administered in combination with a Eribulin mesylate liposomal formulation, and wherein the tumor is breast cancer, gastric cancer, esophageal cancer, small cell lung cancer, colorectal cancer, renal cancer, thymic carcinoma or intrahepatic cholangiocarcinoma.

3. The use according to claim 1 or 2, wherein the PD-1 antibody and the liposomal composition comprising Eribulin mesylate are to be administered simultaneously, separately, continuously, or at a time interval.

4. The use according to claim 1 or 2, wherein the anti-PD-1 antibody is selected from the group consisting of Nivolumab, Pembrolizumab, Cemiplimab, Sintilimab and Toripalimab.

5. The use according to claim 1 or 2, wherein the anti-PD-1 antibody is Nivolumab and wherein Nivolumab is to be administered at 3 mg/kg (body weight) every 2 weeks, at 240 mg every 2 weeks, at 360 mg every 3 weeks or at 480 mg every 4 weeks.

6. The use according to claim 1 or 2, wherein the anti-PD-1 antibody is Nivolumab and wherein Nivolumab is to be intravenously administered at 360 mg on day 1 of a 21-day cycle and Eribulin mesylate is to be intravenously administered at 1.7 to 2.1 mg/m^2 (body surface area).

7. The use according to claim 1 or 2, wherein the anti-PD-1 antibody is Nivolumab and wherein Nivolumab is to be intravenously administered at 240 mg on days 1 and 15 of a 28-day cycle and Eribulin mesylate is to be intravenously administered at 1.1 to 1.4 mg/m^2 (body surface area).

8. The use according to claim 1 or 2, wherein the tumor is breast cancer, gastric cancer, esophageal cancer, small cell lung cancer, colorectal cancer or renal cancer.

9. The use according to claim 1 or 2, wherein the tumor is breast cancer.

10. The use according to claim 1 or 2, wherein the tumor is gastric cancer.

11. The use according to claim 1 or 2, wherein the tumor is esophageal cancer.

12. The use according to claim 1 or 2, wherein the tumor is small cell lung cancer.

13. The use according to claim 1 or 2, wherein the tumor is intrahepatic cholangiocarcinoma.